12:00 AM
 | 
Oct 18, 2016
 |  BC Extra  |  Top Story

LLS launches collaborative AML trial

On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia.

The trial will enroll newly diagnosed AML patients aged 60 or older. Patients will be screened using a genomic profiling assay from Foundation Medicine Inc. (NASDAQ:FMI) for hematologic malignancies. Patients will then be assigned...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >